[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-lymphocytic-leukemia:immunoglobulin-heavy-chain-variable-domain":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Lymphocytic Leukemia","Immunoglobulin Heavy Chain Variable Domain",4,[8,16,23,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07566364","Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",[12],"Phase 2","RECRUITING","2026-08-26T02:19:03.581490Z","2026-05-13T02:55:06.731598Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03219450","A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.",[20],"Phase 1","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.583843Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.287166Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[33],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z"]